新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群医药巨头警告：可能“弊大于利”

金吾财讯10-07

金吾财讯 | 临床数据显示，注射礼来公司(LLY)的药物后，其中有25%的体重减轻来自于肌肉等瘦体重(即去脂体重，=体重-脂肪重量)的减少，而注射诺和诺德(NVO)的药物后则有40%的体重减轻是由于瘦体重的下降。当前，Regeneron公司(REGN)正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。据报道，当前，Regeneron公司正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。Yancopoulos同时也担任该司的首席科学官，他表示：“临床研究表明，接受新型减肥药物(GLP-1)治疗的患者，其肌肉流失速度远快于通过饮食或运动减肥的人群，这会给他们带来健康问题。”

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2473172231?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","is_english":false,"pubTime":"2024-10-07 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473172231","market":"hk","top_or_hot":-1,"title":"新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群 医药巨头警告：可能“弊大于利”","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 临床数据显示，注射<a href=\"https://laohu8.com/S/LLY\">礼来</a>公司(LLY)的药物后，其中有25%的体重减轻来自于肌肉等瘦体重(即去脂体重，=体重-脂肪重量)的减少，而注射<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>(NVO)的药物后则有40%的体重减轻是由于瘦体重的下降。当前，Regeneron公司(REGN)正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。据报道，当前，Regeneron公司正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。Yancopoulos同时也担任该司的首席科学官，他表示：“临床研究表明，接受新型减肥药物(GLP-1)治疗的患者，其肌肉流失速度远快于通过饮食或运动减肥的人群，这会给他们带来健康问题。”</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群 医药巨头警告：可能“弊大于利”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群 医药巨头警告：可能“弊大于利”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-07 20:21 北京时间&nbsp;&nbsp;&nbsp;<a href=280631><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 临床数据显示，注射礼来公司(LLY)的药物后，其中有25%的体重减轻来自于肌肉等瘦体重(即去脂体重，=体重-脂肪重量)的减少，而注射诺和诺德(NVO)的药物后则有40%的体重减轻是由于瘦体重的下降。当前，Regeneron公司(REGN)正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。据报道，当前，Regeneron公司正在推进研究一种新的药物实验，旨在减少由减肥药物...</p>\n\n<a href=\"280631\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BK4W5M84.HKD","symbol_name":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","start_time":0,"source_url":"280631","article_id":"2473172231","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473172231","pubTimestamp":1728303714,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 临床数据显示，注射礼来公司 的药物后，其中有25%的体重减轻来自于肌肉等瘦体重的减少，而注射诺和诺德的药物后则有40%的体重减轻是由于瘦体重的下降。据报道，当前，Regeneron公司正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。Yancopoulos同时也担任该司的首席科学官，他表示：“临床研究表明，接受新型减肥药物治疗的患者，其肌肉流失速度远快于通过饮食或运动减肥的人群，这会给他们带来健康问题。”","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK1161":"生物科技","LU0882574055.USD":"富达全球健康医疗A ACC","BK4581":"高盛持仓","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4590":"PTP","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","NVO":"诺和诺德","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","REGN":"再生元制药公司","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4532":"文艺复兴科技持仓","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","09939":"开拓药业-B","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LLY":"礼来","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4588":"碎股","GLP":"全球合伙","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC"},"translate_title":"New weight loss drugs (GLP-1) may cause muscle loss faster than the general population Pharmaceutical giants warn: May \"do more harm than good\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"GLP":1,"REGN":0.9,"NVO":0.9,"LLY":0.9},"content_text":"金吾财讯 | 临床数据显示，注射礼来公司(LLY)的药物后，其中有25%的体重减轻来自于肌肉等瘦体重(即去脂体重，=体重-脂肪重量)的减少，而注射诺和诺德(NVO)的药物后则有40%的体重减轻是由于瘦体重的下降。当前，Regeneron公司(REGN)正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。据报道，当前，Regeneron公司正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。Yancopoulos同时也担任该司的首席科学官，他表示：“临床研究表明，接受新型减肥药物(GLP-1)治疗的患者，其肌肉流失速度远快于通过饮食或运动减肥的人群，这会给他们带来健康问题。”","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473172231"}

新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群 医药巨头警告：可能“弊大于利”

精彩评论

新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群医药巨头警告：可能“弊大于利”